Multiple Myeloma and EasyM Resource Centre.
Featured
Measurable Residual Disease and Decision-Making in Multiple Myeloma
Iain Rogers2025-02-28T09:22:26-05:00August 3rd, 2024|Case Studies|
Publications, Posters & Case Studies
Jenna Kerry2025-06-11T15:55:48-04:00
Discontinuation of Maintenance Therapy in Multiple Myeloma Guided by Multimodal Measurable Residual Disease Negativity (MRD2STOP)
Jenna Kerry2025-06-11T15:55:48-04:00June 11th, 2025|Publication|
Jenna Kerry2025-05-21T11:04:11-04:00
Minimal Residual Disease as a Primary Endpoint in Multiple Myeloma
Jenna Kerry2025-05-21T11:04:11-04:00May 21st, 2025|Publication|
Jenna Kerry2025-05-15T10:08:14-04:00
Blood-based Measurable Residual Disease Measurement by Clonotypic Mass Spectrometry is Prognostic in Patients with Multiple Myeloma Undergoing Autologous Hematopoietic Cell Transplant
Jenna Kerry2025-05-15T10:08:14-04:00May 14th, 2025|Publication|